AbbVie ABBV-1480 Phase 3 Lung Cancer Trial: Recruiting; Start Date Still Estimated
ClinicalTrials.gov lists NCT07756645 as recruiting, with 2026-09-22 marked as an estimated start. Registry update posted 2026-10-20.
This article records evidence available when published or updated. Registration dates are not proof of trial enrollment; check the original sources for current status.
Update, October 21, 2026: The official ClinicalTrials.gov record now lists this study as recruiting. Its study start field remains 2026-09-22, estimated. An actual start date is UNKNOWN from this record; recruiting status alone does not change the date field to actual. The latest registry update was posted 2026-10-20. This update supersedes the recruitment and start-date assessment in our September 23 correction.
What is registered
AbbVie registered a Phase 3 study of ABBV-1480 with chemotherapy against pembrolizumab with chemotherapy as first-line treatment for locally advanced or metastatic non-small cell lung cancer. The study record identifies it as NCT07756645 and lists planned enrollment of 940 participants. Enrollment is an estimate in the protocol, not a count of participants already enrolled. The registered design and comparisons describe what investigators intend to test; they do not establish safety, efficacy, or a completed clinical milestone.
Choose a company and prepare a question. Run it manually after confirming the question and reviewing the required credits.
Prepared research question
AbbVie ABBV-1480 Phase 3 Lung Cancer Trial: which company evidence supports or challenges the article?
Traceable citations · Unknowns marked
How to read the current record
Recruitment and the study start date are separate registry fields. The recruiting label supports a recruitment-status update, while the estimated date remains a forecast. It must not be presented as a confirmed first-participant date. The protocol lists 940 participants as estimated enrollment; this is a target, not the number already enrolled. The registered phase is Phase 3.
Recruitment status, estimated completion dates, reported results, and regulatory decisions are distinct milestones. Check the latest official record for subsequent changes before using the trial in a research decision. This article reports the registry fields retrieved on October 21, 2026, rather than a prediction of clinical or investment outcomes.
Follow the evidence
The original article URL is retained so earlier links reach this update. BioSniper's company page provides a starting point for related research; each tracked event still requires its own source and date verification.
Source: ClinicalTrials.gov study NCT07756645, retrieved October 21, 2026. Latest posted update: 2026-10-20.